Working… Menu

Phase I Study on Multiple Oral Dosing of CG100649

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01154790
Recruitment Status : Completed
First Posted : July 1, 2010
Last Update Posted : January 28, 2016
Information provided by (Responsible Party):
CrystalGenomics, Inc.

Brief Summary:
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of 3 escalating loading and maintenance dose regimens of CG100649 administered orally for 7 total days in healthy volunteers.

Condition or disease Intervention/treatment Phase
Healthy Drug: CG100649 Drug: Placebo Drug: Naproxen Phase 1

Detailed Description:
Data dictionary that contains detailed descriptions of each variable used by the registry, including the source of the variable, coding information if used CTCAE and normal ranges if relevant.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind Study Evaluating the Upper Gastrointestinal Safety on Multiple Doses of CG100649 in Healthy Subjects
Study Start Date : June 2010
Actual Primary Completion Date : January 2011
Actual Study Completion Date : January 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Naproxen

Arm Intervention/treatment
Experimental: CG100649
By the amount of doses, the groups are classified
Drug: CG100649
6 subjects: study drug 2 subjects: placebo

Drug: Placebo
6 subjects: study drug 2 subjects: placebo

Active Comparator: Naproxen
By the amount of doses, the groups are classified
Drug: Placebo
6 subjects: study drug 2 subjects: placebo

Drug: Naproxen
6 subjects: study drug 2 subjects: placebo
Other Name: NAXEN

Placebo Comparator: Placebo
By the amount of doses, the groups are classified
Drug: Placebo
6 subjects: study drug 2 subjects: placebo

Primary Outcome Measures :
  1. Safety (normal results for safety tests) [ Time Frame: 27days ]

    Cardiovascular: BP,ECG, Holter monitoring

    GI: Fecal occult blood

    Kidney: Urine electrolyte test

    Adverse events

    Physical examination, vital signs

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. 19-55 years old. Body weight is over 50 kg (male) and over 45 kg (female). Body weights must be within 20% of ideal body weight for their height according to the ideal body weight table.
  2. No significant congenital/chronic disease. No symptoms in physical examination.
  3. Appropriate subjects as determined by past medical history, laboratory tests, serology and urinalysis.
  4. Be able to understand the objective, method of the study, the characteristics of investigational drug, and comply with the requirement of the study. Subject must provide written informed consent prior to study participation.

Exclusion Criteria:

  1. History or presence of liver, kidney, or nervous system disease, respiratory disorders, endocrinological disorders, hemato-oncologic, cardiovascular or psychiatric or cognitive disorders.
  2. History of gastrointestinal disorders (bleeding, ulceration, hemorrhoids, piles) or disorders of absorption, distribution, metabolism, excretion.
  3. History of known hypersensitivity to drugs including CG100649.
  4. After taking a rest in sitting position for 3 minutes, subjects who have low blood pressure (Systolic BP ≤ 90 mmHg or Diastolic BP ≤ 50 mmHg) or high blood pressure (Systolic BP ≥ 150 mmHg or Diastolic BP ≥ 100 mmHg).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01154790

Layout table for location information
Korea, Republic of
Asan Medical Center
Seoul, Korea, Republic of
Sponsors and Collaborators
CrystalGenomics, Inc.
Layout table for investigator information
Study Director: Seonggu Ro CrystalGenomics, Inc.
Layout table for additonal information
Responsible Party: CrystalGenomics, Inc. Identifier: NCT01154790    
Other Study ID Numbers: CG100649-1-04
First Posted: July 1, 2010    Key Record Dates
Last Update Posted: January 28, 2016
Last Verified: June 2010
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by CrystalGenomics, Inc.:
healthy volunteers
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gout Suppressants
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action